Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Esquivel-Moynelo, 2020 RPCEC00000307

IFN gamma (n=41) vs. standard of care (n=38)

randomized controlled trial   high risk of bias

Studied treatment

IFN alpha-2b plus IFN gamma (HeberFERON)
Subcutaneous treatment with a co-lyophilized combination of 3.0 MIU IFN-α2b and 0.5 MIU IFN-γ (HeberFERON, CIGB, Havana, Cuba), twice a week for two weeks,

Control treatment

IFN alpha-2b alone (Heberon)
Intramuscular injection of 3.0 MIU IFN-α2b (Heberon® Alpha R, CIGB, Havana, Cuba), thrice a week.

Additionally, all patients received lopinavir-ritonavir 200/50 mg every 12 h and chloroquine 250 mg every 12 h (standard of care).

Patients

COVID 19 hospitalized

Adult (≥19 years-old) patients with RT-PCR confirmed SARS-CoV-2, ECOG functional status ≥ 2 (Karnofsky ≥ 70%), and voluntariness by signing the informed consent.

Method

Open-label

Single center, Military Central Hospital “Luis Diaz Soto”, Havana, Cuba.

Phase 2.

Remark